AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 19650808
Drug: Systemic heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic heparin anticoagulation without antiaggregation [Group 2 (G2)]
Trial: 10357429
Drug: 0.12% aspartame
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% aspartame solution
Trial: 10357429
Drug: 24% polycose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24% polycose solution
Trial: 31074660
Drug: Self-Management program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-Management program plus Physical Therapy
Trial: 31074660
Drug: Control Group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control Group (standard medical treatment)
Trial: 31842940
Drug: Triple therapy
RxNorm normalized name: MigreLief Triple Therapy with Puracol Caplet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple therapy (methotrexate, hydroxychloroquine, and sulfasalazine)
Trial: 29046405
Drug: Total potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total potato consumption in PREDIMED (81.9 ± 40.6 g/d)
Trial: 29046405
Drug: Total potato
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total potato consumption in SUN (52.7 ± 33.6 g/d)
Trial: 19092350
Drug: Intravenous hypocaloric
RxNorm normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hypocaloric nutrition starting 20 hours before the operation
Trial: 21823168
Drug: Increased dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased dose of olanzapine (OLZ)
Trial: 9580762
Drug: High-iron formula
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-iron formula (12.7 mg/L of elemental iron)
Trial: 9580762
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula (2.3 mg/L of elemental iron)
Trial: 8206405
Drug: Groshong catheter
RxNorm normalized name: CATHETER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Groshong catheter for intraperitoneal therapy
Trial: 12357164
Drug: Intravenous analgesia
RxNorm normalized name: Analgesic Balm GRX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous analgesia (n = 16)
Trial: 29685179
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of oral doxycycline (400 mg) and metronidazole (400 mg)
Trial: 26661344
Drug: Patient-performed daily
RxNorm normalized name: Perform
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patient-performed daily spirometry and positive expiratory pressure (PEP)
Trial: 25109873
Drug: Adjunctive aripiprazole
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjunctive aripiprazole with antidepressant
Trial: 21119408
Drug: Low-level laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-level laser therapy (820 nm, 3 J/cm2, 300-mW output power), applied 2 times per week for a total of 10 sessions.
Trial: 16169561
Drug: IFN beta‐1a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a, 44 mcg subcutaneously (sc) three times weekly (tiw) (Rebif)
Trial: 16169561
Drug: IFN beta‐1a,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN beta‐1a, 30 mcg intramuscularly (im) once weekly (qw) (Avonex)
Trial: 11755292
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (4 IU subcutaneously every other day for three months)
Trial: 11720604
Drug: Candesartan 32
RxNorm normalized name: candesartan 32 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan 32 mg once daily
Trial: 8546999
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole at a daily dose of 75 mg b.i.d. for 12 weeks, with possible increase to 150 mg b.i.d. after 1 month if no improvement
Trial: 8546999
Drug: Oral liarozole
RxNorm normalized name: letrozole Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral liarozole
Trial: 381957
Drug: Ticrynafen (250‐‐500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ticrynafen (250‐‐500 mg/day)
Trial: 381957
Drug: Hydrochlorothiazide (50‐‐100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (50‐‐100 mg/day)
Trial: 27470470
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (10.5 therapist visits, 38.6 minutes of arm therapy, 16 repetitions of functional tasks per visit)
Trial: 26177655
Drug: JNJ-42847922 (3-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: JNJ-42847922 (3-30 mg/kg)
Trial: 14581115
Drug: Naloxone (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (0.01 mg/kg)
Trial: 11061771
Drug: Cisapride (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (0.2 mg/kg/dose 3 times/day)
Trial: 6512867
Drug: Standard Couple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard Couple Therapy
Trial: 6512867
Drug: Group Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group Therapy
Trial: 24844747
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg oral tiagabine
Trial: 22825365
Drug: Larazotide acetate
RxNorm normalized name: Larazotide
DrugBank: Larazotide (DB05645)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Larazotide acetate (0.25, 1, 4, or 8 mg)
Trial: 20116087
Drug: Clopidogrel (75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel (75 mg) and acetyl salicylic acid (100 mg) after coronary stenting for myocardial infarction
Trial: 18050208
Drug: Methotrexate ≤20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate ≤20 mg weekly
Trial: 16181235
Drug: LGH (0.10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LGH (0.10 mg/day)
Trial: 16181235
Drug: SGH (mean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SGH (mean dose 0.48 mg/day)
Trial: 30476335
Drug: Intervention tools
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intervention tools (e.g., prompts and standing desks)
Trial: 24456128
Drug: Biologically equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologically equivalent dose (BED) Gy3 ≥ 80 Gy
Trial: 23016867
Drug: Metronidazole (MTZ)
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole (MTZ) 400 mg thrice a day (TID) for 14 days
Trial: 23016867
Drug: Metronidazole +
RxNorm normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Metronidazole + Amoxicillin (MTZ+AMX) 500 mg TID for 14 days
Trial: 23016867
Drug: Chlorhexidine 0.12%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine 0.12% rinsed twice a day (BID) for 2 months
Trial: 11481402
Drug: Touchi-extract (TE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Touchi-extract (TE) 0.3 g before each meal for 3 months
Trial: 9951916
Drug: Desferrioxamine infused
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desferrioxamine infused at a dose of 80 mg/kg per cycle
Trial: 2561147
Drug: Enalapril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (5 mg once a day)
Trial: 1841828
Drug: Phenobarbital (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital (20 mg/kg loading dose)
Trial: 594674
Drug: Preoperative irradiation
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative irradiation (total dose of 3,300 rads in 3 weeks)
Trial: 24010675
Drug: LY2196044 (125
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY2196044 (125 or 250 mg/d)
Trial: 20941459
Drug: Apixaban (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apixaban (5 mg bid, 10 mg bid or 20 mg qd)
Trial: 18583436
Drug: n‐3 PUFA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n‐3 PUFA supplements
Trial: 12170445
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2) plus cisplatin 75 mg/m(2) every 3 weeks
Trial: 11441409
Drug: docetaxel 75
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 75 mg/m(2) plus carboplatin to an area under the curve of 6 mg/mL x min every 3 weeks
Trial: 11441409
Drug: vinorelbine 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vinorelbine 25 mg/m(2) weekly plus cisplatin 100 mg/m(2) monthly
Trial: 9608923
Drug: Hemisynthesis diosmine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hemisynthesis diosmine 600 mg, one tablet per day taken in the morning
Trial: 9608923
Drug: Usual tablet
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual tablet formulation of diosmine 300 mg taken twice a day (morning and evening)
Trial: 8001524
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg retinol as retinyl palmitate every 4 months for 1 year
Trial: 2648213
Drug: Acyclovir, 800
RxNorm normalized name: Acyclovir, 800 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 800 mg 5 times daily for 7 days
Trial: 20217150
Drug: Gabapentin 200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 200 mg and imipramine 10 mg every 12 h orally (G400-I group)
Trial: 20217150
Drug: Gabapentin 200
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 200 mg every 12 h orally (G400 group)
Trial: 20217150
Drug: Gabapentin 400
RxNorm normalized name: gabapentin 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabapentin 400 mg every 12 h orally (G800 group)
Trial: 20217150
Drug: Imipramine 10
RxNorm normalized name: trimipramine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipramine 10 mg every 12 h orally (I group)
Trial: 9589244
Drug: NPL insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPL insulin
Trial: 16048153
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard injection without Vibraject)
Trial: 2006119
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of intramuscular polyestradiol phosphate (PEP) and oral ethinyl estradiol
Trial: 2006119
Drug: Intramuscular PEP
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular PEP alone
Trial: 6332893
Drug: Co-trimoxazole (twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (twice daily for 6 months)
Trial: 31859575
Drug: Biological mesh
RxNorm normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biological mesh (Veritas®)
Trial: 31859575
Drug: Both biological
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both biological and synthetic meshes
Trial: 22137185
Drug: SPARX computerized
RxNorm normalized name: tiotropium
DrugBank: Tiotropium (DB01409)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SPARX computerized Cognitive Behavioural Therapy (cCBT) completed over 5 weeks (n=20)
Trial: 19770739
Drug: Intra-aortic balloon
RxNorm normalized name: somatropin
DrugBank: Somatotropin (DB00052)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intra-aortic balloon pump (IABP) therapy
Trial: 19770739
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (without IABP)
Trial: 12042265
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg mifepristone orally followed by 800 microg vaginal misoprostol
Trial: 7570567
Drug: Amrinone (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amrinone (bolus 1 mg/kg, continuous infusion of 5‐10 micrograms/kg/min)
Trial: 2160667
Drug: Intensive combined
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive combined chemotherapy (B)
Trial: 2160667
Drug: High-dose half-body
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose half-body irradiation (HBI) (A)
Trial: 6448131
Drug: Topical 1
RxNorm normalized name: urea topical 10% topical cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1 percent clindamycin phosphate (Cleocin T)
Trial: 6448131
Drug: Oral tetracycline
RxNorm normalized name: Tetracycline
DrugBank: Tetracycline (DB00759)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tetracycline 500 mg/day
Trial: 23537750
Drug: Split-dose sodium
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen administered 2 to 6 hours before colonoscopy
Trial: 23537750
Drug: Split-dose sodium
RxNorm normalized name: influenza A virus (H1N1) antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-dose sodium picosulphate/magnesium oxide/anhydrous citric acid (Citrafleet(®)) regimen
Trial: 19118083
Drug: Ketoconazole 200
RxNorm normalized name: ketoconazole 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole 200 mg twice daily for 9 days, coadministered with a single 5‐mg dose of fingolimod on the 4th day of ketoconazole treatment.
Trial: 19118083
Drug: Fingolimod 5
RxNorm normalized name: fingolimod 500 MCG Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 5 mg single dose in period 1 without ketoconazole.
Trial: 9599555
Drug: Cardioselective beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta 1 antagonists for more than three months
Trial: 9599555
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (never received beta-blockers)
Trial: 9599555
Drug: Cardioselective beta
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardioselective beta 1 antagonists
Trial: 9208342
Drug: 100 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 micrograms cerivastatin as a 1-minute bolus infusion
Trial: 9208342
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms cerivastatin orally as tablets
Trial: 9208342
Drug: 200 micrograms
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 micrograms cerivastatin as an oral solution
Trial: 7119508
Drug: Intramuscular administration
RxNorm normalized name: Japanese Encephalitis vaccine for intramuscular administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular administration of 96.6 and 135 million units of human interferon-alpha over 12-15 weeks
Trial: 7119508
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of human interferon-alpha (double blind, placebo-controlled)
Trial: 7119508
Drug: Intralesional injections
RxNorm normalized name: flumethasone
DrugBank: Flumethasone (DB00663)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intralesional injections of human interferon-alpha
Trial: 29258890
Drug: Galantamine (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine (8 mg)
Trial: 26085028
Drug: Insulin glargine/glulisine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin glargine/glulisine once daily
Trial: 26085028
Drug: Biphasic insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Biphasic insulin aspart/aspart protamine 30/70 twice daily
Trial: 19175979
Drug: Ziprasidone (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ziprasidone (80 to 160 mg/day)
Trial: 19175979
Drug: Risperidone (6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (6 to 10 mg/day)
Trial: 17156266
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of D‐amphetamine + physiotherapy
Trial: 17156266
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of L‐dopa + physiotherapy
Trial: 17156266
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of D‐amphetamine + 50 mg of L‐dopa + physiotherapy
Trial: 15669780
Drug: Mismanagement of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mismanagement of insulin
Trial: 15669780
Drug: Eating 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eating 3 meals a day, getting insulin every day, and more assistance with meals
Trial: 12057081
Drug: Selective serotonin
RxNorm normalized name: Selective serotonin (5HT1) agonists
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective serotonin re‐uptake inhibitors (SSRIs)
Trial: 3542323
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg sustained‐release furosemide preparation (FR)
Trial: 3542323
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg standard furosemide tablet (F)
Trial: 29724115
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group from two archived randomized control trials (RCTs) assessing intentions, normative beliefs, values, and substance use.
Trial: 27855660
Drug: Fentanyl 2
RxNorm normalized name: fentanyl 2.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 2 mcg/kg (Group F)
Trial: 27855660
Drug: Oxycodone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxycodone 0.2 mg/kg (Group O)
Trial: 25164220
Drug: Sequential combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential combination therapy (iloprost: 10 µg/inhalation, 6 times per day for 6 months, then add oral tadalafil (5 mg/d) till 12 months, n = 32)
Trial: 25164220
Drug: Upfront combination
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upfront combination therapy (iloprost: 10 µg/inhalation, 6 times per day combined with oral tadalafil (5 mg) for 12 months, n = 36)
Trial: 22613154
Drug: Acetaminophen (APAP)
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen (APAP) + Ketorolac
Trial: 18544952
Drug: PEG‐IFNalpha‐2a monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFNalpha‐2a monotherapy
Trial: 15780524
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (free-treatment)
Trial: 10333139
Drug: HBY 097
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBY 097 (non-nucleoside inhibitor of HIV-1 reverse transcriptase)
Trial: 1909603
Drug: Dihydroergokryptine 10
RxNorm normalized name: α-dihydroergocryptine
DrugBank: Dihydro-alpha-ergocryptine (DB11274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergokryptine 10 mg b.i.d.
Trial: 1909603
Drug: Dihydroergotamine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine 5 mg b.i.d. (controlled release)
Trial: 6238741
Drug: New traction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New traction treatment called auto‐traction
Trial: 6238741
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of Colles' fracture with electromagnetic fields
Trial: 30498836
Drug: Standard primary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard primary healthcare treatment
Trial: 27824811
Drug: Olaparib 400
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib 400 mg b.i.d. (capsules)
Trial: 25282564
Drug: Moisturizer applied
RxNorm normalized name: MOISTURIZER
DrugBank: Homosalate (DB11064)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moisturizer applied daily during the first 32 weeks of life
Trial: 21803547
Drug: Inhaled corticosteroid/bronchodilator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroid/bronchodilator therapy (continuing treatment)
Trial: 16390805
Drug: Phenobarbital 20
RxNorm normalized name: phenobarbital 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenobarbital 20 mg/kg IV
Trial: 9585793
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (200 ml double-strength, three times a day for 2 days)
Trial: 7658286
Drug: Beta-carotene supplementation,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation, large doses (exact dosage not specified)
Trial: 2670423
Drug: 0.5 mg
RxNorm normalized name: biotin 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg norethindrone and 0.035 mg ethinyl estradiol (NET + EE)
Trial: 2670423
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg norgestrel and 0.03 mg ethinyl estradiol (Ng + EE)
Trial: 31345107
Drug: Enalapril (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enalapril (10 mg/d, n=31)
Trial: 31345107
Drug: Perindopril (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (5 mg/d, n=31)
Trial: 25746727
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment for 12 weeks after each dialysis session.
Trial: 23176986
Drug: sufentanil 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sufentanil 5.0 μg